All adult patients seen in rheumatology consultation at the Montpellier Hospital
With inflammatory rheumatism (rheumatoid arthritis or spondyloarthritis).
Treated (or in the process of being treated at the end of the consultation) by etanercept or adalimumab
In whom the biomedical treatment already used should in principle be renewed without modification (patient deemed good responder and well tolerant of the treatment)
Or where biomedical initiation has just been indicated during the consultation
Member of a social security scheme
Informed and written consent
You may not be if
Unable to understand information (not fluent in the French language, severe cognitive impairment, etc.)
Known intolerance to one of the proposed biosimilar excipients
Vulnerable persons: pregnant woman, minor patient, deprived of liberty, under guardianship or under curatorship
Clareo Health | Information and Acceptability of Biosimilars
